Prev Close | 66.21 |
Open | 66.46 |
Day Low/High | 66.45 / 67.32 |
52 Wk Low/High | 53.63 / 71.70 |
Volume | 4.56M |
Prev Close | 66.21 |
Open | 66.46 |
Day Low/High | 66.45 / 67.32 |
52 Wk Low/High | 53.63 / 71.70 |
Volume | 4.56M |
Exchange | NASDAQ |
P/E Ratio | 51.70 |
Div & Yield | N.A. (N.A) |
Both biotech stocks are at or near 52-week lows, but don't deserve to be.
This at-the-money, long put shooter is a high risk trade, so use discretionary capital.
This portfolio cannot be trusted to be diversified enough.
Top pharmaceutical companies are paving the way to a cure for Alzheimer's, a degenerative disease that is affecting millions around the world.
Adamis Pharmaceuticals and Pieris Pharmaceuticals are names to watch.
Eli Lilly, AstraZeneca and vTv Therapeutics show why it's best to stay away from biotech's black hole.
I continue to see these names as bargains in the biotech and biopharma space.
Here are 2 small caps I continue to see as bargains in this space.
These dividend payers compete in businesses that I'm interested in and believe in -- and they pay me to own the shares.
Data and industry conferences will likely be catalysts for shares in the space.
Novartis' deal for AveXis has ignited a rally in other gene-therapy concerns.
A look at possible second-quarter M&A activity in the biotech sector.
Surviving the age of Amazon is all there is to retailers' earnings.
The FDA granted fast track designation to imetelstat as a potential treatment for adults with with transfusion-dependent anemia.
Verastem Inc., Pieris Pharmaceuticals and Intra-Cellular Therapies all have promising products.
As with Adamas Pharmaceuticals, circling key milestone dates on your calendar can prove beneficial.
As with Adamas Pharmaceuticals, circling key milestone dates on your calendar can prove beneficial.
This week's bullish and bearish reversal patterns.
AstraZeneca shares are tanking.
The collapse of the Sino-American session on tariffs and access translates into market action for investors, and inaction on improved trade.
Several firms hiked price targets on Portola into the $70s this week.
Several firms hiked price targets on Portola into the $70s this week.
U.K. Prime Minister Theresa May says technology companies have to do more to combat hate speech.
Stocks end the session mixed after Nordstrom and J.C. Penney become the latest retail names to report on a weak quarter.
A guide to keep track of all the companies reporting first quarter financial results today -- making sense of what's important and disregarding what's not.
The stock is headed toward a bullish golden cross.
Stocks declined on Tuesday as wild weather stifled activity and led to low volume.
Why the name is sagging, and what it will take to spur the sector higher.
Most of the 10 best stocks of the bull market did it their way.